Evidence map›Paper›PMID 28067899›Full record

ArticleNature medicine2017

Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome.

Jorge Oller, Nerea Méndez-Barbero, E Josue Ruiz, Silvia Villahoz, Marjolijn Renard, Lizet I Canelas, Ana M Briones, Rut Alberca, Noelia Lozano-Vidal, María A Hurlé and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 174 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Fibronectin-induced overactivation of αNature communications · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Adamts1 and Cyst Expansion in Polycystic Kidney Disease.Journal of the American Society of Nephrology : JASN · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Jorge OllerGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Nerea Méndez-BarberoGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
E Josue RuizGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Silvia VillahozGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Marjolijn RenardCenter for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium.
Lizet I CanelasGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Ana M BrionesDepartment of Pharmacology, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Rut AlbercaGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Noelia Lozano-VidalGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
María A HurléCardiovascular Surgery and Department of Physiology and Pharmacology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Facultad de Medicina, Universidad de Cantabria, Santander, Spain.
Dianna MilewiczDivision of Medical Genetics, University of Texas, Houston, USA.
Arturo EvangelistaServei de Cardiologia, Hospital Vall d'Hebron, Barcelona, Spain.
Mercedes SalaicesDepartment of Pharmacology, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
J Francisco NistalCardiovascular Surgery and Department of Physiology and Pharmacology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Facultad de Medicina, Universidad de Cantabria, Santander, Spain.
Luis Jesús Jiménez-BorregueroCentro Nacional de Investigaciones Cardiovasculares and Hospital de la Princesa, Madrid, Spain.ORCID http://orcid.org/0000-0001-5870-237X
Julie De BackerDepartment of Pharmacology, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.ORCID http://orcid.org/0000-0001-8878-1507
Miguel R CampaneroDepartment of Cancer Biology, Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain.
Juan Miguel RedondoGene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
Spanish National Centre for Cardiovascular Research · ESUniversidad Autónoma de Madrid · ESUniversidad de Cantabria · ESConsejo Superior de Investigaciones Científicas · ESGhent University Hospital · BEVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heritable thoracic aortic aneurysms and dissections (TAAD), including Marfan syndrome (MFS), currently lack a cure, and causative mutations have been identified for only a fraction of affected families. Here we identify the metalloproteinase ADAMTS1 and inducible nitric oxide synthase (NOS2) as therapeutic targets in individuals with TAAD. We show that Adamts1 is a major mediator of vascular homeostasis, given that genetic haploinsufficiency of Adamts1 in mice causes TAAD similar to MFS. Aortic nitric oxide and Nos2 levels were higher in Adamts1-deficient mice and in a mouse model of MFS (hereafter referred to as MFS mice), and Nos2 inactivation protected both types of mice from aortic pathology. Pharmacological inhibition of Nos2 rapidly reversed aortic dilation and medial degeneration in young Adamts1-deficient mice and in young or old MFS mice. Patients with MFS showed elevated NOS2 and decreased ADAMTS1 protein levels in the aorta. These findings uncover a possible causative role for the ADAMTS1-NOS2 axis in human TAAD and warrant evaluation of NOS2 inhibitors for therapy.

Indexed as

ADAMTS1 ProteinAdipokinesAdultAgedAnimalsAortaAortic AneurysmAortic Aneurysm, ThoracicAortic DissectionDisease Models, AnimalEnzyme InhibitorsFemaleFibrillin-1Gene Knockdown TechniquesHaploinsufficiencyHumansADAMTS1 ProteinADAMTS1 protein, humanAdamts1 protein, mouseAdipokinesEnzyme InhibitorsFbn1 protein, mouseFibrillin-1NG-Nitroarginine Methyl EsterNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanNos2 protein, mouse

Identifiers

PMID28067899
OpenAlexW2569369624

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.